MedDataX Logo

Effects of Zolmitriptan on Sensory Transmission After Spinal Cord Injury

NCT ID: NCT01587170

Last Updated: 2012-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

13 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-31

Study Completion Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

After spinal cord injury, patients develop a spastic syndrome that is characterized by hyperactive reflexes, increased muscle tone, clonus and involuntary muscle spasms. The neuronal mechanisms behind the development of spasticity remain largely unknown, though animal experiments have shown that changes occur both at the level of the motoneuron and sensory neurons. This project aims to examine the changes that occur in the modulation of sensory afferent transmission after spinal cord injury, and how these changes can contribute to the triggering and initiation of muscle spasms after chronic spinal cord injury in humans.

It is known that after spinal cord injury, the majority of descending sources of monoamines, such as serotonin (5HT), are abolished. Animal experiments have shown that 5HT receptors on sensory neurons in the spinal cord are responsible for inhibiting sensory transmission. As a result, after spinal cord injury these receptors are no longer activated below an injury, resulting in the production of large, long excitatory responses in the motoneuron when sensory are activated. This large sensory activation of the motoneuron can, in turn, activate a long response in the motoneuron to produce an involuntary muscle spasm. The aim of our study is to determine whether, similar to animal experiments, the 5HT1 receptors are responsible for sensory inhibition in spinal cord injured subjects, and whether activating these receptors (through the 5HT1 agonist Zolmitriptan) will restore the normal inhibition of sensory transmission that is lost after injury, thereby resulting in a decrease in the initiation of involuntary muscle spasms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Cord Injuries Muscle Spasticity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

spasticity spinal cord injury zolmitriptan

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Uninjured control subjects

Uninjured, control subjects who are not taking any of the contraindicated drugs.

No interventions assigned to this group

Spinal-cord injured subjects

Patients who have suffered a spinal cord injury (\>1year ago).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have suffered a trauma to the spinal cord at least 1 year prior. In addition, subjects must exhibit some degree of spasticity as determined by having an Ashworth Spasticity Score greater than 1 in the ankle or knee.

Exclusion Criteria

* If patients have damage to the nervous system other than to the spinal cord
* Pregnant women
* Elderly Patients (\> 65 years)
* Alcoholic Patients
* History of ischemic cardiac, cerebrovascular or peripheral vascular syndromes
* Valvular heart disease or cardiac arrhythmias
* Other significant underlying cardiovascular disease (atherosclerotic disease, congenital heart disease)
* Uncontrolled or severe hypertension
* Hemiplegic, basilar or ophthalmologic migraine
* Hypersensitivity to Zolmitriptan or any component of the formulation
* History of Autonomic Dysreflexia
* Patients taking:
* Ergot-containing drugs
* Other 5HT1 Agonists
* MAO Inhibitors
* Cimetidine and other 1A2 Inhibitors
* Propranolol
* Selective Serotonin and Norepinephrine Reuptake Inhibitors
* Acetaminophen
* Metoclopramide
* Xylometazoline
* Oral Contraceptives
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Alberta

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Monica A Gorassini, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Alberta

Ming Chan, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Alberta

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alberta

Edmonton, Alberta, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Murray KC, Stephens MJ, Rank M, D'Amico J, Gorassini MA, Bennett DJ. Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. J Neurophysiol. 2011 Aug;106(2):925-43. doi: 10.1152/jn.01011.2010. Epub 2011 Jun 8.

Reference Type BACKGROUND
PMID: 21653728 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.scialberta.ca/

Related Info

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pro00019967

Identifier Type: -

Identifier Source: org_study_id